Vis enkel innførsel

dc.contributor.authorHofmann, Matthiasen_US
dc.contributor.authorMcCormack, Emmeten_US
dc.contributor.authorMujic, Majaen_US
dc.contributor.authorRoßberg, Mailaen_US
dc.contributor.authorBernd, Augusten_US
dc.contributor.authorBereiter-Hahn, Jürgenen_US
dc.contributor.authorGjertsen, Bjørn Toreen_US
dc.contributor.authorWiig, Helgeen_US
dc.contributor.authorKippenberger, Stefanen_US
dc.date.accessioned2015-04-16T12:20:06Z
dc.date.available2015-04-16T12:20:06Z
dc.date.issued2009-08eng
dc.identifier.issn1522-8002
dc.identifier.urihttps://hdl.handle.net/1956/9816
dc.description.abstractElevated tumor interstitial fluid pressure (TIFP) is a characteristic of most solid tumors. Clinically, TIFP may hamper the uptake of chemotherapeutic drugs into the tumor tissue reducing their therapeutic efficacy. In this study, a means of modulating TIFP to increase the flux of macromolecules into tumor tissue is presented, which is based on the rationale that elevated plasma colloid osmotic pressure (COP) pulls water from tumor interstitium lowering the TIFP. Concentrated human serum albumin: (20% HSA), used as an agent to enhance COP, reduced the TIFP time-dependently from 8 to 2 mm Hg in human tumor xenograft models bearing A431 epidermoid vulva carcinomas. To evaluate whether this reduction facilitates the uptake of macromolecules, the intratumoral distribution of fluorescently conjugated dextrans (2.5 mg/ml) and cetuximab (2.0 mg/ml) was probed using novel time domain nearinfrared fluorescence imaging. This method permitted discrimination and semiquantification of tumor-accumulated conjugate from background and unspecific probe fluorescence. The coadministration of 20% HSA together with either dextrans or cetuximab was found to lower the TIFP significantly and increase the concentration of the substances within the tumor tissue in comparison to control tumors. Furthermore, combined administration of 20%HSA plus cetuximab reduced the tumor growth significantly in comparison to standard cetuximab treatment. These data demonstrate that increased COP lowers the TIFP within hours and increases the uptake of therapeutic macromolecules into the tumor interstitium leading to reduced tumor growth. This model represents a novel approach to facilitate the delivery of therapeutics into tumor tissue, particularly monoclonal antibodies.en_US
dc.language.isoengeng
dc.publisherElseviereng
dc.rightsAttribution-NonCommercial-NoDerivs CC BY-NC-NDeng
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/eng
dc.titleIncreased plasma colloid osmotic pressure facilitates the uptake of therapeutic macromolecules in a xenograft tumour modelen_US
dc.typePeer reviewed
dc.typeJournal article
dc.date.updated2015-03-31T14:03:18Zen_US
dc.description.versionpublishedVersionen_US
dc.rights.holderCopyright 2009 Neoplasia Press Inc.
dc.identifier.doihttps://doi.org/10.1593/neo.09662
dc.identifier.cristin343274
dc.source.journalNeoplasia
dc.source.4011
dc.source.148
dc.source.pagenumber812-822
dc.subject.nsiVDP::Medical sciences: 700::Basic medical, dental and veterinary sciences: 710eng
dc.subject.nsiVDP::Medisinske fag: 700::Basale medisinske, odontologiske og veterinærmedisinske fag: 710nob


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Attribution-NonCommercial-NoDerivs CC BY-NC-ND
Med mindre annet er angitt, så er denne innførselen lisensiert som Attribution-NonCommercial-NoDerivs CC BY-NC-ND